Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Moderna Inc
(NQ:
MRNA
)
63.93
-2.90 (-4.34%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 1, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Moderna Inc
< Previous
1
2
3
4
5
6
7
8
9
...
15
16
Next >
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Moderna, Lululemon, XPEL, and Nano Nuclear and Encourages Investors to Contact the Firm
September 30, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
Moderna and Cenra Healthcare Enter Joint Agreement to Promote Moderna’s mRNA Respiratory Vaccine Portfolio in Taiwan, Including COVID-19 Vaccines
September 30, 2024
Via
ACCESSWIRE
MODERNA, INC. (NASDAQ: MRNA) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Moderna, Inc. Investors of Upcoming Deadline
September 30, 2024
From
Bernstein Liebhard LLP
Via
GlobeNewswire
Moderna R&D Day Highlights Progress and Strategic Priorities
September 12, 2024
Via
ACCESSWIRE
Moderna’s Canadian Manufacturing Facility Receives Drug Establishment License From Health Canada
September 09, 2024
Via
ACCESSWIRE
Moderna Announces First Participant Dosed in Pivotal Phase 3 Trial of Investigational mRNA Norovirus Vaccine, mRNA-1403
September 30, 2024
Via
ACCESSWIRE
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Moderna, Lululemon, XPEL, and Nano Nuclear and Encourages Investors to Contact the Firm
September 25, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Moderna, Inc. Investors to Secure Counsel Before Important October 8 Deadline in Securities Class Action – MRNA
September 24, 2024
From
The Rosen Law Firm PA
Via
GlobeNewswire
MODERNA, INC. (NASDAQ: MRNA) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Moderna, Inc. Investors of Upcoming Deadline
September 23, 2024
From
Bernstein Liebhard LLP
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Moderna, Lululemon, XPEL, and Nano Nuclear and Encourages Investors to Contact the Firm
September 21, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
3 Beaten-Down Stocks Ready for a Comeback
September 19, 2024
if you're looking for a way to escape the market volatility, here are three stocks that are trading near their 52-week lows with solid catalysts for growth
Via
MarketBeat
Topics
Economy
Exposures
Economy
Moderna, Inc. REMINDER – MRNA Stockholders Should Contact Robbins LLP for Information About the Moderna, Inc. Class Action and Pending Lead Plaintiff Deadline
September 18, 2024
From
Robbins LLP
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Moderna, Lululemon, XPEL, and Nano Nuclear and Encourages Investors to Contact the Firm
September 17, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
Moderna Receives Health Canada Approval For Updated COVID-19 Vaccine Targeting KP.2 Variant Of SARS-COV-2 For Ages Six Months And Older
September 17, 2024
Via
ACCESSWIRE
MODERNA, INC. (NASDAQ: MRNA) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Moderna, Inc. Investors of Upcoming Deadline
September 16, 2024
From
Bernstein Liebhard LLP
Via
GlobeNewswire
Moderna’s Recent Drop: 4 Reasons Bulls See Opportunity
September 16, 2024
Moderna Inc. (NASDAQ: MRNA) made headlines during the pandemic for its messenger ribonucleic acid (mRNA) technology used in its COVID-19 vaccine Spikevax.
Via
MarketBeat
Exposures
COVID-19
Product Safety
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Moderna, Lululemon, XPEL, and Nano Nuclear and Encourages Investors to Contact the Firm
September 13, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Moderna, Lululemon, XPEL, and Nano Nuclear and Encourages Investors to Contact the Firm
September 09, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
MODERNA, INC. (NASDAQ: MRNA) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Moderna, Inc. Investors of Upcoming Deadline
September 09, 2024
From
Bernstein Liebhard LLP
Via
GlobeNewswire
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Moderna, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – MRNA
September 09, 2024
From
The Rosen Law Firm PA
Via
GlobeNewswire
EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna's COVID-19 mRNA Vaccine Targeting the SARS-COV-2 Variant JN.1
September 05, 2024
Via
ACCESSWIRE
Moderna, Inc. Shareholders - Robbins LLP Reminds MRNA Stockholders of the Class Action Lawsuit Against the Company – Seek Counsel Today
September 04, 2024
From
Robbins LLP
Via
GlobeNewswire
Global Coronavirus Therapeutics Market Size Projected to Exceed $16 Billion By the End of 2031
September 04, 2024
EQNX::TICKER_START (NASDAQ:SBFM),(NASDAQ:MRNA),(NYSE:PFE),(NASDAQ:VIR),(NASDAQ:INO) EQNX::TICKER_END
Via
FinancialNewsMedia
Exposures
COVID-19
Global Coronavirus Therapeutics Market Size Projected to Exceed $16 Billion By the End of 2031
September 04, 2024
From
FN Media Group LLC
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Moderna, PDD Holdings, Extreme Networks, and Sprinklr and Encourages Investors to Contact the Firm
September 03, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
Moderna Receives Medicines And Healthcare Products Regulatory Agency (MHRA) Authorization For Updated COVID-19 Vaccine Targeting SARS-COV-2 Variant JN.1
September 03, 2024
Via
ACCESSWIRE
MODERNA, INC. (NASDAQ: MRNA) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Moderna, Inc. Investors of Upcoming Deadline
September 03, 2024
From
Bernstein Liebhard LLP
Via
GlobeNewswire
Taiwan Food & Drug Administration Approves Moderna’s COVID-19 mRNA Vaccine Targeting the SARS-COV-2 Variant JN.1
September 02, 2024
Via
ACCESSWIRE
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Moderna, PDD Holdings, Extreme Networks, and Sprinklr and Encourages Investors to Contact the Firm
August 30, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
Shareholder Rights Law Firm Robbins LLP Urges Moderna, Inc. Stockholders to Seek Counsel for the MRNA Class Action
August 28, 2024
From
Robbins LLP
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
...
15
16
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.